Pfizer/Hospira Epogen Biosimilar Rejected; Relief For Amgen
This article was originally published in Scrip
Executive Summary
Pfizer Inc. sneaked the news into its quarterly earnings call on Oct. 27 that its newly acquired subsidiary Hospira Inc. had received a complete response letter earlier this month from the FDA for its epoetin alfa biosimilar – a product Amgen Inc. has been working desperately through the US court system to keep off the market for a little while longer.